Abbott launches leadless pacemaker in India for slow heart rhythms

The product has also been approved by the US Food and Drug Administration (USFDA)

Abbott, Abbott logo
People who experience slower-than-normal heart rhythm may receive a pacemaker to deliver pulses of electricity to trigger the heart to beat properly. | Photo: Twitter @AbbottNews
Press Trust of India New Delhi
2 min read Last Updated : Nov 22 2024 | 6:55 PM IST

Don't want to miss the best from Business Standard?

Abbott has launched a pacemaker in India for the treatment of patients with slow heart rhythms.
 
Abbott has introduced AVEIR VR single-chamber ventricular leadless pacemaker which has been approved by the Central Drugs Standard Control Organisation, the company said in a statement on Friday. 
The product has also been approved by the US Food and Drug Administration (USFDA). 
"The AVEIR VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options," said Ajay Singh Chauhan, General Manager for Abbott's Cardiac Rhythm Management business in India, Southeast Asia, HK, Taiwan & Korea. 
People who experience slower-than-normal heart rhythm may receive a pacemaker to deliver pulses of electricity to trigger the heart to beat properly. 
Balbir Singh, Chairman Cardiology, Max Superspeciality Hospital said, "Leadless pacemakers address known complications associated with traditional pacemakers." While traditional pacemakers require a chest incision and pocket for the generator along with one or more insulated wires 'known as cardiac leads 'to deliver electricity to the heart, leadless pacemakers do not require a pocket or leads. 
"In some circumstances where we believe a person's therapy needs may change in the future, retrievability also becomes a critical device feature," Vanita Arora, Clinical Lead Electrophysiology, Apollo Hospitals Delhi said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Abbott HealthcareAbbott Indiapacemaker

First Published: Nov 22 2024 | 2:08 PM IST

Next Story